Navigation Links
Corgenix Medical Corp. Announces Launch of Products for Automated Systems
Date:3/2/2010

DENVER, March 2 /PRNewswire-FirstCall/ -- Corgenix Medical Corporation (OTC Bulletin Board: CONX), a worldwide developer and marketer of diagnostic test kits, has announced the availability of its new automation friendly anti-phospholipid assay format.

The new format offers high-volume testing labs the same performance as the currently available Corgenix rapid assay with improved efficiency and high-volume analysis.

"Offering both extended and short assay formats allows us to maintain our leadership position in anti-phospholipid antibody detection," said Douglass Simpson, Corgenix CEO and President. "Our customers can now compete more effectively with enhanced automated performance."

Automated microplate ELISA processing from Corgenix is available for a wide range of anti-phospholipid antibody screening tests, including anti-Cardiolipin (aCL) antibodies, anti-Phosphatidylserine (aPS) antibodies and anti-Beta2 Glycoprotein I IgG antibodies.

As the first company to obtain FDA clearance of its anti-Cardiolipin test, Corgenix maintains its commitment to offer the highest quality tests associated with SLE (lupus) and antiphospholipid syndrome, autoimmune mediated thrombotic diseases. It is estimated that over 3 million individuals in the United States and 10 million worldwide have lupus or lupus-like disorders.

About Corgenix Medical Corporation

Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including the world's only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network. More information is available at www.corgenix.com.

Statements in this press release that are not strictly historical facts are "forward-looking" statements (identified by the words "believe", "estimate", "project", "expect" or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.

SOURCE Corgenix Medical Corporation

Back to top

RELATED LINKS
http://www.corgenix.com

'/>"/>

SOURCE Corgenix Medical Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Corgenix Reports Second Quarter Fiscal 2010 Financial Results
2. Corgenix and BG Medicine Announce Supply Agreement for BGM Galectin-3(TM)
3. Corgenix Reports Financial Results for First Quarter of Fiscal 2010
4. Corgenix to Host Conference Call to Discuss Fiscal 2010 First Quarter Results
5. Corgenix, Tulane Announce Award of NIH Grant Extending Hemorrhagic Fever Virus Product Development Program
6. Corgenix AspirinWorks(R) Test Recognized in POLYCAP Study at ACC.09
7. International Merchant Advisors Reaches Agreement in Principal to Acquire First Medical Marijuana Clinic Operations
8. ATS Medical Announces Fourth Quarter and Full Year 2009 Results
9. First Perry Baromedical Sigma Elite Hyperbaric Chamber with EMR Installed at Stillwater Medical Center
10. Briggs Medical Service Company Receives ISO Registration and CE Mark Certification
11. APC Group, Inc. Reports Multi-Year Deal with Medical Device Manufacturer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... 7, 2016  Palatin Technologies, Inc. ("Palatin") (NYSE ... a previously disclosed underwritten public offering of units ... as sole book-running manager, Roth Capital Partners acted ... as co-manager for the offering. "This ... net proceeds, allowing us to continue advancing bremelanotide ...
(Date:12/7/2016)... , Dec. 7, 2016 DelveInsight,s, ... report provides in depth insights on the ... the Janus Kinase 3 (JAK3) Inhibitors. The ... various stages of development including Discovery, Pre-clinical, ... and Preregistration. Report covers the product clinical ...
(Date:12/7/2016)... YORK , Dec. 7, 2016 ... report on pulmonary drugs studies the current as ... The stakeholders of this report include companies and ... various pulmonary/respiratory drugs and/or drug-device combinations as well ... This report comprises an elaborate executive summary along ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... Healthcare ... Act. Dr. Botelho advocates for the mass media launching of story movements to ... opportunities to share their unfortunate experiences; such a movement can generate the network ...
(Date:12/8/2016)... ... December 08, 2016 , ... Peter ... communities in and around the greater Phoenix metropolitan region, is announcing a charity ... The mission of the Homeless Youth Connection is to promote community awareness of ...
(Date:12/7/2016)... PA (PRWEB) , ... December 07, 2016 , ... ... with the announcement that it is one of the early adopters completing EU-U.S. Privacy ... Framework is designed to provide companies on both sides of the Atlantic with a ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... and deep lines by smoothing and tightening the skin of the face to ... to address facial aging with very little downtime, Silhouette Instalift is a novel, ...
(Date:12/7/2016)... Ca (PRWEB) , ... December 07, 2016 , ... It ... that funding is with useful, properly analyzed data. The team at Beckman Coulter has ... address the 'need for speed' and the need to operate in a GLP (Good ...
Breaking Medicine News(10 mins):